Pharmacotherapy of obsessive-compulsive disorder: Experience with the selective serotonin reuptake inhibitors

Simple item page
dc.contributor.authorVythilingum B.
dc.contributor.authorCartwright C.
dc.contributor.authorHollander E.
dc.date.accessioned2011-05-15T15:59:18Z
dc.date.available2011-05-15T15:59:18Z
dc.date.issued2000
dc.description.abstractSince the introduction of the selective serotonin reuptake inhibitors (SSRIs) a decade ago, they have become first-line agents in the treatment of obsessive-compulsive disorder (OCD). Numerous clinical trials have confirmed their efficacy, and established their superior risk-benefit ratio in comparison with clomipramine, a non-selective serotonin reuptake inhibitor. Relatively higher doses and longer duration of treatment may be necessary to effect a response in OCD, with long-term treatment being required to maintain therapeutic gains. Despite the advances represented by the SSRIs, treatment resistance remains a problem. While no one solution exists, various strategies, including pharmacotherapy augmentation, look promising. (C) 2000 Lippincott Williams and Wilkins.
dc.description.versionConference Paper
dc.identifier.citationInternational Clinical Psychopharmacology
dc.identifier.citation15
dc.identifier.citationSUPPL. 2
dc.identifier.issn2681315
dc.identifier.urihttp://hdl.handle.net/10019.1/11110
dc.subjectcitalopram
dc.subjectclomipramine
dc.subjectfluoxetine
dc.subjectfluvoxamine
dc.subjectparoxetine
dc.subjectplacebo
dc.subjectserotonin uptake inhibitor
dc.subjectsertraline
dc.subjectasthenia
dc.subjectclinical trial
dc.subjectconference paper
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectdose response
dc.subjectdrug efficacy
dc.subjectdrug half life
dc.subjectdrug tolerance
dc.subjectgastrointestinal symptom
dc.subjectheadache
dc.subjecthuman
dc.subjectinsomnia
dc.subjectobsession
dc.subjectpriority journal
dc.subjectpsychopharmacotherapy
dc.subjectrisk benefit analysis
dc.subjecttremor
dc.subjectxerostomia
dc.subjectClinical Trials
dc.subjectDrug Resistance
dc.subjectHumans
dc.subjectObsessive-Compulsive Disorder
dc.subjectSerotonin Uptake Inhibitors
dc.titlePharmacotherapy of obsessive-compulsive disorder: Experience with the selective serotonin reuptake inhibitors
dc.typeConference Paper
Files
Collections
Stellenbosch University - Scopus Publications